360-361 / 2953
Conclusions
IMRT offers opportunities across different sarcomas:
Soft tissue sarcomas – improved conformality to PTV,
reduced dose to normal tissues, sparing of normal
structures (e.g. bone), improved late toxicity?
Bone sarcomas:
Delivery of optimal dose to PTV with normal tissue
sparing (Ewing’s sarcoma)
Dose escalation for more radioresistant tumours
(primary bone sarcomas, chondrosarcoma,
chordoma)
PBT/carbon ions will offer advantage for some
patients, but not easily accessible to all, so IMRT
remains important
44